Clinical Trials Sponsored by 3D Medicines (Sichuan) Co., Ltd.

Total 1050 results

3D Medicines (Sichuan) Co., Ltd.

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Advanced Endometrial Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Not yet recruiting

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Biliary Tract Neoplasms
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Completed

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase I Trial of Envafolimab for Healthy Male Subjects

Healthy Male

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Renal Cell Carcinoma | Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Solid Tumors

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

KN035 for dMMR/MSI-H Advanced Solid Tumors

Solid Tumor

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (KN035-BTC)

Biliary Tract Neoplasms

China
3D Medicines (Beijing) Co., Ltd.

Withdrawn

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China
3D Medicines (Beijing) Co., Ltd.

Not yet recruiting

Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma,Adult
3D Medicines (Beijing) Co., Ltd.

Active, not recruiting

A Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China, United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Huiyu Pharmaceutical Co., Ltd

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Efficacy | Tolerability | Safety

China
Sichuan Baili Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Her2-positive/Low-expression Urinary and Digestive Tract Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Relapsed/Refractory Chronic Lymphocytic Leukemia

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma of Lung | Non-small Cell Lung Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinomas

China
Sichuan Baili Pharmaceutical Co., Ltd.

Terminated

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Colorectal Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Unknown

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Ventricular Fibrillation | Ventricular Tachycardia

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Gastric Cancer | Colorectal Cancer | Esophageal Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Solid Tumor | Urothelial Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Non Small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Non-small Cell Lung Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Triple-negative Breast Cancer and HR+/HER2- BC

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Sichuan Provincial People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy
Sichuan University
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
Sichuan University
Chengdu MedGenCell, Co., Ltd.

Completed

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer

China
Sichuan University
Geneplus-Beijing Co. Ltd.

Recruiting

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Non-small Cell Lung Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

SKB410 for Injection in Solid Tumors

Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of A166 in Patients With Advanced Solid Malignant Tumors

Breast Cancer

China
Sichuan University
Chengdu Brilliant Pharmaceutical Co., Ltd.

Not yet recruiting

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

Small Cell Lung Cancer Extensive Stage

3

Subscribe